Anti-EGFRvIII antibodies and uses thereof
US10738124B2 · kind B2 · utility
2Cited by
17References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2018 |
| Grant date | Aug 11, 2020 |
| Priority date | — |
| Expiry date | Jul 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.